We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

45 hedge funds and large institutions have $8.34M invested in Galectin Therapeutics in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

240% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 5

199% more capital invested

Capital invested by funds: $2.79M → $8.34M (+$5.55M)

188% more call options, than puts

Call options by funds: $784K | Put options by funds: $272K

5% more funds holding

Funds holding: 43 → 45 (+2)

0.94% more ownership

Funds ownership: 9.7% → 10.65% (+0.94%)

Holders
45
Holders Change
+2
Holders Change %
+4.65%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
17
Reduced
5
Closed
2
Calls
$784K
Puts
$272K
Net Calls
+$512K
Net Calls Change
+$449K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$317K
2
Charles Schwab
Charles Schwab
California
+$230K
3
BlackRock
BlackRock
New York
+$195K
4
Morgan Stanley
Morgan Stanley
New York
+$125K
5
DADC
D.A. Davidson & Co
Montana
+$115K

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$31K
2
Neuberger Berman Group
Neuberger Berman Group
New York
-$8.82K
3
BCA
Benchmark Capital Advisors
New York
-$6.03K
4
Bank of America
Bank of America
North Carolina
-$5.25K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$1.92K
Name Holding Trade Value Shares
Change 		Change in
Stake
DADC
1
D.A. Davidson & Co
Montana
$1.84M +$115K +76,167 +11%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.7M +$317K +210,504 +40%
AG
3
Advisor Group
Arizona
$1.01M +$102K +67,475 +18%
BCA
4
Benchmark Capital Advisors
New York
$447K -$6.03K -4,000 -2%
Charles Schwab
5
Charles Schwab
California
$351K +$230K +152,300 New
CCM
6
Courage Capital Management
Tennessee
$299K – – –
BlackRock
7
BlackRock
New York
$298K +$195K +129,678 New
US Bancorp
8
US Bancorp
Minnesota
$274K +$42.3K +28,087 +31%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$250K +$1.17K +774 +0.7%
Morgan Stanley
10
Morgan Stanley
New York
$206K +$125K +83,020 +1,285%
Neuberger Berman Group
11
Neuberger Berman Group
New York
$199K -$8.82K -5,850 -6%
VKH
12
Virtu KCG Holdings
New York
$198K +$2.4K +1,592 +2%
Northern Trust
13
Northern Trust
Illinois
$165K +$40.3K +26,716 +59%
GWM
14
Geneos Wealth Management
Colorado
$130K +$6.03K +4,000 +8%
CCB
15
Cutter & Co Brokerage
Missouri
$130K +$31K +20,600 +57%
BSW
16
Buckingham Strategic Wealth
Missouri
$115K +$75.4K +50,000 New
Citadel Advisors
17
Citadel Advisors
Florida
$80K +$52.3K +34,709 New
NPF
18
Norris Perne & French
Michigan
$70K – – –
BIP
19
Brandes Investment Partners
California
$66K +$43K +28,500 New
JMPWA
20
JP Morgan Private Wealth Advisors
California
$60K – – –
SWP
21
Stratos Wealth Partners
Ohio
$56K – – –
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$54K – – –
Bank of New York Mellon
23
Bank of New York Mellon
New York
$48K -$1.92K -1,273 -6%
Goldman Sachs
24
Goldman Sachs
New York
$40K +$3.05K +2,026 +13%
RG
25
Rathbones Group
United Kingdom
$38K – – –
1
2

GALT Hedge Fund Activity: Q1 2017 in Review

45 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2017, worth a combined $8.34M — up 199% from $2.79M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new GALT positions and 2 closed out — a net gain of 5 holders — while 17 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $317K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $31K sold.

  • 45 institutional investors held Galectin Therapeutics (GALT) as of Q1 2017, up from 43 in Q4 2016.
  • Funds reported $8.34M of Galectin Therapeutics stock for Q1 2017, up 199% quarter-over-quarter.
  • 7 funds opened new Galectin Therapeutics positions in Q1 2017 and 2 closed out, a net change of +5 holders.
  • The largest Galectin Therapeutics buyer in Q1 2017 was Vanguard Group, an estimated $317K added.
  • The largest Galectin Therapeutics seller in Q1 2017 was A.R.T. Advisors, an estimated $31K sold.

Based on aggregated 13F filings for Q1 2017.